Gender differences in the effects of methylphenidate on energy intake in young adults: a preliminary study

Goldfield, Gary S.; Lorello, Claudio; Cameron, Jameason D.; Chaput, Jean‐Philippe

doi:10.1139/h11-098

Cited by 10 publications

(7 citation statements)

References 17 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, chronic MP treatment was associated with sex-dependent differences in fluid and food intake as previous studies similarly reported (Goldfield et al, 2007, Goldfield et al, 2011, Davis et al, 2012). Although previous studies collectively agree that chronic MP treatment modulates fluid and food intake, their findings have been inconsistent.…”

Section: Discussionsupporting

confidence: 89%

Recovery from behavior and developmental effects of chronic oral methylphenidate following an abstinence period

Martin¹,

Fricke²,

Vijayashanthar³

et al. 2018

Pharmacology Biochemistry and Behavior

View full text Add to dashboard Cite

Chronic oral methylphenidate (MP) exposure in rats is associated with numerous developmental and behavioral consequences. The present study investigated the persistence of the effects of chronic oral MP exposure after abstinence from MP use. Male and female rats were exposed to daily orally self-administered water, low dose MP (LD), or high dose (HD) MP for 13 weeks, followed by a 4-week abstinence period. Fluid, food consumption and bodyweights were monitored and animals were tested for locomotor activity, anxiety- and depressive-like symptoms, learning and memory, and social behavior during both the treatment and abstinence phases of the experiment. During treatment, MP attenuated bodyweight regardless of sex, but increased food and fluid consumption in females and males by 20.7% and 30.1%, respectively. MP also increased locomotor activity in both males and females observed as increased distance travelled in an open field. (59.1% and 95.9%, respectively) and increased locomotor activity in the home cage over a 24-hour circadian cycle (45.5% and 63.0%). Additionally, MP exerted an anxiolytic effect observed as increased time spent in the open arms of an elevated plus maze (31.1% in HD males, 59.2% in HD females), and an increased latency to immobility in a forced swim test (330% in HD males, 418% in HD females). The effects of MP (bodyweight, consumption, locomotion, anxiolytic, and anti-depressive) were, almost without exception, eliminated during the abstinence period. MP had no impact on learning and memory performance as measured by a T-maze, or social behavior during treatment. These findings suggest that the behavioral consequences of chronic oral MP treatment in our preclinical model are reversible in rats following an abstinence period from use of the drug.

show abstract

Section: Discussionsupporting

confidence: 89%

Recovery from behavior and developmental effects of chronic oral methylphenidate following an abstinence period

Martin¹,

Fricke²,

Vijayashanthar³

et al. 2018

Pharmacology Biochemistry and Behavior

View full text Add to dashboard Cite

show abstract

“…Psychostimulants suppress appetite [27, 28] and may lead to body weight reduction following chronic exposure [29]. Indeed, during the treatment phase, we observed decreased fluid intake in both LD and HD treated rats compared to the water treated rats, and decreased food intake and body weight only in the HD treated rats.…”

Section: Discussionmentioning

confidence: 64%

Weekday-only chronic oral methylphenidate self-administration in male rats: Reversibility of the behavioral and physiological effects

Carias¹,

Fricke²,

Vijayashanthar³

et al. 2019

Behavioural Brain Research

View full text Add to dashboard Cite

Methylphenidate (MP) is a commonly prescribed psychostimulant for Attention Deficit Hyperactivity Disorder (ADHD). We recently reported behavioral and developmental effects of chronic MP use in healthy rats. The current study investigated how interrupting chronic MP treatment with weekend abstinence altered the behavioral and physiological consequences of chronic MP treatment, and if prolonged abstinence would reverse the observed effects. Male Sprague Dawley rats were assigned to one of three treatment groups: water (W); low dose (LD) MP; and high dose (HD) MP. For 13 weeks, rats had access to drink from a bottle containing 4 mg/kg MP (LD), 30 mg/kg MP (HD) or water (W) for 1 hour, and 10 mg/kg MP (LD), 60 mg/kg MP (HD) or water (W) for the next 7 hours, each week day. During weekends, all animals received only water as well as throughout the 5-week-long abstinence phase, which immediately followed the treatment phase. Throughout the treatment phase, regardless of weekend abstinence, chronic MP resulted in significant decreased food and fluid intake and body weight. Also, HD MP exposure resulted in the following behavioral effects: increased open field and circadian locomotor activity; increased latency to immobility and decreased time spent immobile in the forced swim test; increased center activity in the open field and percent of time spent in an open arm of the elevated-plus-maze; and increased social affiliation and memory in the Crawley’s three chamber sociability test. During the prolonged (5-week) abstinence phase, all these effects were reversed while HD treated rats increased their fluid intake. These results indicated that intermittent brief abstinence periods (weekend’s off-treatment) produced the same behavioral and developmental effects as those previously reported with chronic (7 days/week) MP treatment, but were reversible following a prolonged abstinence period (5 weeks).

show abstract

“…For instance, treatment with this drug lowers body weight faster in male than in female rats and reduces total fluid intake in male only . In addition, in normal‐weight humans, methylphenidate decreases energy intake more in men than in women, whereas in patients with obesity, it significantly reduces appetite, cravings, and snack‐food intake only in women . A stronger anorectic effect in women than men has been observed in the response to methylphenidate also in binge eating disorders .…”

Section: Phentermine/topiramate Combinationmentioning

confidence: 99%

Gender‐related issues in the pharmacology of new anti‐obesity drugs

et al. 2018

View full text Add to dashboard Cite

Four new medicines-liraglutide, lorcaserin, bupropion/naltrexone, and phentermine/ topiramate-have been recently added to the pharmacological arsenal for obesity treatment and could represent important tools to manage this epidemic disease. To achieve satisfactory anti-obesity goals, the use of these new medicines should be optimized and tailored to specific patient subpopulations also by applying dose adjustments if needed. In the present review, we posit that gender could be among the factors influencing the activity of the new obesity drugs both because of pharmacokinetic and pharmacodynamic factors. Although evidence from premarketing clinical studies suggested that no dose adjustment by gender is necessary for any of these new medicines, these studies were not specifically designed to identify genderrelated differences. This observation, together with the strong theoretical background supporting the hypothesis of a gender-dimorphic response, strongly call upon an urgent need of new real-life data on gender-related difference in the pharmacology of these new obesity drugs.

show abstract

Gender differences in the effects of methylphenidate on energy intake in young adults: a preliminary study

Cited by 10 publications

References 17 publications

Recovery from behavior and developmental effects of chronic oral methylphenidate following an abstinence period

Recovery from behavior and developmental effects of chronic oral methylphenidate following an abstinence period

Weekday-only chronic oral methylphenidate self-administration in male rats: Reversibility of the behavioral and physiological effects

Gender‐related issues in the pharmacology of new anti‐obesity drugs

Contact Info

Product

Resources

About